CHAMBER OF COMMERCE OF THE U.S.A.
CHAMBER OF COMMERCE OF THE U.S.A.
AB
The past 12 months
Clients
1
past 12 months
Filings
2
past 12 months
Agencies contacted
Agriculture, Dept of (USDA)Centers For Medicare and Medicaid Services (CMS)Commerce, Dept of (DOC)Executive Office of the President (EOP)HOUSE OF REPRESENTATIVESHealth & Human Services, Dept of (HHS)Internal Revenue Service (IRS)Labor, Dept of (DOL)SENATEState, Dept of (DOS)Treasury, Dept ofU.S. Trade & Development Agency (USTDA)U.S. Trade Representative (USTR)
Specific issues
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
H.R. 6294, Childhood Diabetes Reduction Act of 2025 H.R. 7291, GRAS Oversight and Transparency Act S. 3122, Better FDA Act of 2025 Various issues relating to Generally Recognized As Safe (GRAS) FDA review process; proposals to reform the definition of ultra-processed foods, including stricter nutritional standards and warning labels; federal preemption for policies related to food labeling and ingredient bans
Various issues relating to pharmaceutical price controls imposed under the Medicare Drug Pricing Negotiation Program of the Inflation Reduction Act; imposition of MFN style price controls of pharmaceutical products within Medicare and Medicaid; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; TRUMP AMERICA AI Act and policies related to AI proposals that impact health care to create a uniform national framework; 2027 Medicare Advantage and Part D Advance Notice
Clients
Sources
This profile is built from the public record: filings in the U.S. Senate Lobbying Disclosure Act system. lda.senate.gov ↗